Skip to main content
Clinical Trials/NCT05125159
NCT05125159
Unknown
Not Applicable

Randomized Trial of Angioplasty Guidewire-Assisted Transseptal Puncture Technique Versus Conventional Technique for Left Atrial Access in Left Atrial Appendage Occlusion

RenJi Hospital1 site in 1 country150 target enrollmentJanuary 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
RenJi Hospital
Enrollment
150
Locations
1
Primary Endpoint
Total transseptal puncture time
Last Updated
4 years ago

Overview

Brief Summary

This will be a prospective, single-blinded, three-center, randomized, controlled trial comparing the effectiveness and safety of angioplasty guidewire-assisted transseptal puncture (GW-TSP) technique to transseptal left atrial (LA) access with conventional transseptal puncture with standard transseptal equipment (CON-TSP) in patients undergoing left atrial appendage occlusion (LAAO) procedure for atrial fibrillation. The targeted population will consist of patients with atrial fibrillation undergoing LAAO.

Detailed Description

Transseptal catheterization is a critical step for left atrial interventions (atrial fibrillation ablation, LA appendage closure, mitral valve interventions). The availability of suitable tools and techniques is essential to safely perform the TSP, effectively deliver radiofrequency lesions, deploy LA devices, and anticipate difficult procedural situations in which complications may arise. Historically, a conventional Brockenbrough (BRK) needle has been used for this procedure to mechanically puncture the fossa ovalis, which has been well described in the literature. Although generally safe, serious complications such as perforation of the atrial wall or aorta can occur. This study is intended to assess the safety, performance and usability of the angioplasty guidewire in facilitating access to the left atrium during LAAO procedures for the treatment of atrial fibrillation (AF). Moreover, the study will assess the impact of the GW-TSP on procedural times, including time to achieve left atrial accesses, total procedure times, total fluoroscopy time. The study is a prospective, single-blinded, three-center, randomized, controlled trial. Enrolled subjects who meet the study inclusion/exclusion criteria will be evaluated during the LAAO procedures and followed until release from hospital post procedure per institutional standard of care. After 30 days, patient will be contacted by telephone to obtain information on their clinical condition and any adverse events; if necessary, a clinic visit may be performed when required by the physician.

Registry
clinicaltrials.gov
Start Date
January 1, 2021
End Date
January 1, 2023
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient is referred to receive a LAAO procedure for atrial fibrillation, requiring transseptal access and LA catheterization
  • Patients greater than 18 years of age
  • Patient has signed the informed consent form and is willing to participate in the clinical study and data collection

Exclusion Criteria

  • Previous left atrial (LA) ablation or LA surgery
  • Active Intracardiac Thrombus
  • Pre-existing pulmonary vein stenosis or PV stent
  • Pre-existing hemidiaphragmatic paralysis
  • Contraindication to anticoagulation or radiocontrast materials
  • Cardiac valve prosthesis
  • Myocardial infarction, PCI / PTCA, or coronary artery stenting during the 3-month period preceding the consent date
  • Cardiac surgery during the three-month interval preceding the consent date
  • Significant congenital heart defect (including atrial septal defects or PV abnormalities but not including PFO)
  • Significant chronic kidney disease (CKD - eGFR \<30 µMol/L)

Outcomes

Primary Outcomes

Total transseptal puncture time

Time Frame: Intraprocedural assessment (within 24 hours)

in minutes and seconds. (Total time required for left atrial access)

Secondary Outcomes

  • Time from sheath in superior vena cava to sheath in fossa ovalis(Intraprocedural assessment (measured in seconds))
  • contrast volume(During or immediately after procedure)
  • Time from needle in fossa ovalis to needle in left atrial(Intraprocedural assessment (measured in seconds))
  • Time from sheath in left atrial to sheath in pulmonary vein(Intraprocedural assessment (measured in seconds))
  • Total fluoroscopy time(in seconds)
  • Total procedural time(in minutes)
  • Time from needle in left atrial to sheath in left atrial(Intraprocedural assessment (measured in seconds))
  • Procedure related complication rate(Acute peri-procedural complications will be defined as occurring within 30 days of LAAO: during or immediately after procedure, up to 1 day after procedure, up to 30 days after procedure)

Study Sites (1)

Loading locations...

Similar Trials